Tenaya Therapeutics Enters Strategic Collaboration with Alnylam, Securing Up to $10M Upfront and $1.13B in Milestones
TNYA sits 78% above its 52-week low of $0.36.
Summary
Tenaya Therapeutics has entered a research collaboration with Alnylam Pharmaceuticals, receiving an upfront payment of up to $10 million and eligibility for up to $1.13 billion in development, regulatory, and sales-based milestones.
Key Events · M&A and Partnerships · TNYA
-
Strategic Collaboration with Alnylam Pharmaceuticals
Tenaya Therapeutics has partnered with Alnylam Pharmaceuticals for a research collaboration focused on discovering and validating novel gene targets for cardiovascular disease.
-
Significant Upfront Payment Received
The company will receive an upfront payment of up to $10.0 million from Alnylam, providing a substantial cash injection for its operations.
-
Potential for Over $1 Billion in Milestone Payments
Tenaya is eligible to receive up to an aggregate of $1.13 billion in development, regulatory, and sales-based milestones for products directed to Company-nominated targets.
-
Exclusive Licensing and Research Focus
Tenaya granted Alnylam an exclusive, worldwide license for collaboration targets, with Alnylam taking sole responsibility for development, manufacturing, regulatory, and commercialization post-validation activities.
Analysis · TNYA · Life Sciences
This collaboration with Alnylam Pharmaceuticals is a highly significant event for Tenaya Therapeutics, providing a substantial upfront cash infusion relative to its market capitalization and validating its gene target discovery platform. The potential for over $1 billion in milestone payments, while contingent, represents a massive long-term value proposition. This strategic partnership with a major pharmaceutical company offers critical non-dilutive funding and external validation, which is particularly impactful given the recent pattern of significant insider selling by a 10% owner. The agreement extends Tenaya's financial runway and de-risks its research efforts in cardiovascular disease, shifting development and commercialization costs for successful targets to Alnylam.
At the time of this filing, TNYA was trading at $0.64 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $125.9M. The 52-week trading range was $0.36 to $2.35. This filing was assessed with positive market sentiment and an importance score of 9 out of 10.